Open Access
Open access
Nature Communications, volume 14, issue 1, publication number 1078

Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response

Publication typeJournal Article
Publication date2023-02-25
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor16.6
ISSN20411723
General Chemistry
General Biochemistry, Genetics and Molecular Biology
Multidisciplinary
General Physics and Astronomy
Abstract

Protein arginine methyltransferase (PRMT) 5 is over-expressed in a variety of cancers and the master transcription regulator E2F1 is an important methylation target. We have explored the role of PRMT5 and E2F1 in regulating the non-coding genome and report here a striking effect on long non-coding (lnc) RNA gene expression. Moreover, many MHC class I protein-associated peptides were derived from small open reading frames in the lncRNA genes. Pharmacological inhibition of PRMT5 or adjusting E2F1 levels qualitatively altered the repertoire of lncRNA-derived peptide antigens displayed by tumour cells. When presented to the immune system as either ex vivo-loaded dendritic cells or expressed from a viral vector, lncRNA-derived peptides drove a potent antigen-specific CD8 T lymphocyte response, which translated into a significant delay in tumour growth. Thus, lncRNA genes encode immunogenic peptides that can be deployed as a cancer vaccine.

Citations by journals

1
Science Signaling
Science Signaling, 1, 4.76%
Science Signaling
1 publication, 4.76%
Non-coding RNA
Non-coding RNA, 1, 4.76%
Non-coding RNA
1 publication, 4.76%
Current Opinion in Immunology
Current Opinion in Immunology, 1, 4.76%
Current Opinion in Immunology
1 publication, 4.76%
Expert Opinion on Drug Discovery
Expert Opinion on Drug Discovery, 1, 4.76%
Expert Opinion on Drug Discovery
1 publication, 4.76%
Biomedicines
Biomedicines, 1, 4.76%
Biomedicines
1 publication, 4.76%
Cancer Gene Therapy
Cancer Gene Therapy, 1, 4.76%
Cancer Gene Therapy
1 publication, 4.76%
Frontiers in Immunology
Frontiers in Immunology, 1, 4.76%
Frontiers in Immunology
1 publication, 4.76%
Trends in Genetics
Trends in Genetics, 1, 4.76%
Trends in Genetics
1 publication, 4.76%
Cardiovascular Research
Cardiovascular Research, 1, 4.76%
Cardiovascular Research
1 publication, 4.76%
Nature Reviews Clinical Oncology
Nature Reviews Clinical Oncology, 1, 4.76%
Nature Reviews Clinical Oncology
1 publication, 4.76%
Biomolecules
Biomolecules, 1, 4.76%
Biomolecules
1 publication, 4.76%
Nature Reviews Genetics
Nature Reviews Genetics, 1, 4.76%
Nature Reviews Genetics
1 publication, 4.76%
Journal of Biomolecular Structure and Dynamics
Journal of Biomolecular Structure and Dynamics, 1, 4.76%
Journal of Biomolecular Structure and Dynamics
1 publication, 4.76%
Amino Acids
Amino Acids, 1, 4.76%
Amino Acids
1 publication, 4.76%
Cell Biochemistry and Function
Cell Biochemistry and Function, 1, 4.76%
Cell Biochemistry and Function
1 publication, 4.76%
Vaccines
Vaccines, 1, 4.76%
Vaccines
1 publication, 4.76%
Trends in Pharmacological Sciences
Trends in Pharmacological Sciences, 1, 4.76%
Trends in Pharmacological Sciences
1 publication, 4.76%
1

Citations by publishers

1
2
3
4
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 4, 19.05%
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 19.05%
Springer Nature
Springer Nature, 4, 19.05%
Springer Nature
4 publications, 19.05%
Elsevier
Elsevier, 3, 14.29%
Elsevier
3 publications, 14.29%
Taylor & Francis
Taylor & Francis, 2, 9.52%
Taylor & Francis
2 publications, 9.52%
American Association for the Advancement of Science (AAAS)
American Association for the Advancement of Science (AAAS), 1, 4.76%
American Association for the Advancement of Science (AAAS)
1 publication, 4.76%
Frontiers Media S.A.
Frontiers Media S.A., 1, 4.76%
Frontiers Media S.A.
1 publication, 4.76%
Oxford University Press
Oxford University Press, 1, 4.76%
Oxford University Press
1 publication, 4.76%
Wiley
Wiley, 1, 4.76%
Wiley
1 publication, 4.76%
1
2
3
4
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Barczak W. et al. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response // Nature Communications. 2023. Vol. 14. No. 1. 1078
GOST all authors (up to 50) Copy
Barczak W., Carr S. M., LIU G., Munro S., Nicastri A., Li L., Hutchings C., Ternette N., Klenerman P., Kanapin A., Samsonova A., La Thangue N. B. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response // Nature Communications. 2023. Vol. 14. No. 1. 1078
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41467-023-36826-0
UR - https://doi.org/10.1038%2Fs41467-023-36826-0
TI - Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response
T2 - Nature Communications
AU - Barczak, Wojciech
AU - Carr, Simon Mark
AU - LIU, GENG
AU - Munro, Shonagh
AU - Nicastri, Annalisa
AU - Li, Lian
AU - Hutchings, Claire
AU - Ternette, Nicola
AU - Klenerman, Paul
AU - Kanapin, Alexander
AU - Samsonova, Anastasia
AU - La Thangue, Nick B.
PY - 2023
DA - 2023/02/25 00:00:00
PB - Springer Nature
IS - 1
VL - 14
PMID - 36841868
SN - 2041-1723
ER -
BibTex
Cite this
BibTex Copy
@article{2023_Barczak,
author = {Wojciech Barczak and Simon Mark Carr and GENG LIU and Shonagh Munro and Annalisa Nicastri and Lian Li and Claire Hutchings and Nicola Ternette and Paul Klenerman and Alexander Kanapin and Anastasia Samsonova and Nick B. La Thangue},
title = {Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response},
journal = {Nature Communications},
year = {2023},
volume = {14},
publisher = {Springer Nature},
month = {feb},
url = {https://doi.org/10.1038%2Fs41467-023-36826-0},
number = {1},
doi = {10.1038/s41467-023-36826-0}
}
Found error?